| 07.11 00:22 | dpa-AFX: Gilead Sciences Inc. Q3 Profit Decreases, But Beats Estimates |
| 06.11 23:36 | dpa-AFX: *GILEAD SCIENCES Q3 EPS $1.00 VS. $1.73 YEAR AGO |
| 06.11 23:35 | dpa-AFX: *GILEAD SCIENCES Q3 EPS $1.00 VS. $1.73 YEAR AGO |
| 06.11 12:02 | dpa-AFX: Gilead Sciences Q3 24 Earnings Conference Call At 4:30 PM ET |
| 20.10 09:23 | dpa-AFX: Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment |
| 17.10 09:35 | dpa-AFX: *BERNSTEIN STARTET GILEAD SCIENCES MIT 'OUTPERFORM' - ZIEL 105 USD |
| 17.10 09:35 | dpa-AFX: *BERNSTEIN STARTS GILEAD SCIENCES WITH 'OUTPERFORM' - PRICE TARGET 105 USD |
| 08.10 03:25 | dpa-AFX: Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir |
| 02.10 16:37 | dpa-AFX: *HETERO ENTERS LICENSING AGREEMENT WITH GILEAD TO EXPAND LENACAPAVIR ACCESS FOR HIV IN 120 HIGH-INCIDENCE COUNTRIES |
| 02.10 15:36 | dpa-AFX: Gilead Partners 6 Pharma Cos. To Provide Generic Lenacapavir In High-incidence Countries |
| 02.10 14:34 | dpa-AFX: *GILEAD PARTNERS WITH SIX GENERIC MAKERS FOR ROYALTY-FREE LICENSING OF LENACAPAVIR TO BOOST HIV PREVENTION ACCESS |
| 24.09 10:26 | dpa-AFX: Gilead Recalls COVID-19 Drug Veklury For Injection |
| 12.09 14:52 | dpa-AFX: Gilead: Lenacapavir Reduces HIV Infections By 96% In PURPOSE 2 Trial |
| 12.09 14:42 | dpa-AFX: *GILEAD: TWICE-YEARLY LENACAPAVIR FOR HIV PREVENTION REDUCED HIV INFECTIONS BY 96% FROM SECOND PHASE 3 CLINICAL TRIAL |
| 10.09 14:17 | dpa-AFX: Gilead Sciences To Work With Genesis To Apply AI Platform To Discover, Advance Therapies |
| 10.09 14:10 | dpa-AFX: *GENESIS SECURES $35 MLN UPFRONT FROM GILEAD |
| 10.09 14:06 | dpa-AFX: *GILEAD AND GENESIS THERAPEUTICS TO DISCOVER AND DEVELOP NOVEL, SMALL MOLECULE THERAPIES ACROSS MULTIPLE TARGETS |
| 18.08 07:44 | dpa-AFX: Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out |
| 15.08 06:03 | dpa-AFX: Gilead Sciences' Livdelzi Receives Accelerated FDA Approval For Primary Biliary Cholangitis |
| 11.08 17:21 | dpa-AFX: Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray |
|
|
